10q10k10q10k.net
Outlook Therapeutics, Inc.

Outlook Therapeutics, Inc.OTLKEarnings & Financial Report

Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)

Outlook Therapeutics, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing ophthalmic biologic therapies for patients with unmet medical needs. Its core pipeline targets common sight-threatening eye conditions, with operations spanning North America, Europe, and key Asia-Pacific regional markets.

Q1 2026Q4 2025Q2 2025Q1 2025Q1 2023

Revenue

$-18.5K

Gross Profit

N/A

Operating Profit

$-12.4M

Net Profit

$-46.4M

Gross Margin

N/A

Operating Margin

66974.0%

Net Margin

250552.4%

YoY Growth

99.4%

EPS

$-1.50

Outlook Therapeutics, Inc. Q2 FY2025 Financial Summary

Outlook Therapeutics, Inc. reported revenue of $-18.5K (up 99.4% YoY) for Q2 FY2025, with a net profit of $-46.4M (up 59.4% YoY) (250552.4% margin).

Key Financial Metrics

Total Revenue$-18.5K
Net Profit$-46.4M
Gross MarginN/A
Operating Margin66974.0%
Report PeriodQ2 FY2025

Outlook Therapeutics, Inc. Quarterly Revenue & Net Profit History

Outlook Therapeutics, Inc. results over the last 5 reported quarters, including revenue, net profit and year-over-year growth.

QuarterRevenueRevenue YoYNet ProfitNet Margin
Q1 FY2026$0—$-23.1MN/A
Q4 FY2025$-264.2K+60.3%$-13.3M5032.2%
Q2 FY2025$-18.5K+99.4%$-46.4M250552.4%
Q1 FY2025$48.9K-74.1%$17.4M35550.9%
Q1 FY2023$-2.4M-596.5%$-18.7M762.2%

Income Statement

Q1 2023Q1 2025Q2 2025Q4 2025Q1 2026
Revenue$-2.4M$48881$-18502$-264156$0
YoY Growth-596.5%-74.1%99.4%60.3%N/A

Balance Sheet

Q1 2023Q1 2025Q2 2025Q4 2025Q1 2026
Assets$62.7M$17.0M$19.1M$18.6M$18.2M
Liabilities$46.9M$67.3M$51.5M$50.8M$56.8M
Equity$15.8M$-50.3M$-32.5M$-32.2M$-38.5M

Cash Flow

Q1 2023Q1 2025Q2 2025Q4 2025Q1 2026
Operating CF$-8.9M$-11.0M$-16.6M$-12.4M$-14.9M